What is MuXroom?
Expressing foreign genes (gene X) in mushrooms.
The concept of MuXroom:
By producing therapeutic proteins in mushrooms, MycoMagic expands the values of mushrooms from nutrition to functions such as healthcare, disease prevention and treatment.
X can be:
a.Green fluorescent protein from jellyfish
b.Genes for pest prevention
c.Nutrients
d.Enzymes
e.Antigens for vaccinations and treatments
f.Antigens for allergy
Mushroom Molecular Pharming
A.Mushroom molecular pharming uses transgenic mushrooms to produce therapeutic proteins, including enzymes, antibodies and antigens for vaccination
B.Advantages of using mushrooms for molecular pharming
a.Mushrooms are GRAS (generally recognized as safe), suitable for use as oral vaccines.
b.Rich in dietary fibers, vitamins, minerals, essential amino acids; low on calories.
c.Medicinal properties of polysaccharides, triterpenes and immunomodulatory proteins.
d.Year round, short growth cycles.
e.Cultivation using agricultural waste such as sawdust, straw and bran.
f.Space saving vertical cultivation by stacking.
g.Closed system cultivation, preventing cross-contamination.
Providing the 4th Major Function to Mushrooms
Mushroom molecular pharming provides the 4th major function
Function No. 1: nutritional value
a.Proteins
b.Dietary fibers
c.B vitamins
d.Ergosterols and minerals
Function No. 2: flavors and taste
Function No. 3: health benefits
a.Polysaccharides
b.Triterpenes
c.Immunomodulatory proteins
Function No. 4: disease prevention and treatment
Hepatitis B Prevention Shiitake Mushrooms
(Lentinula edodes)
‧Hep B surface antigens expression in shiitake mushrooms
‧Fruiting body development
‧Stimulated Hep B antibody production in mice
Hepatitis B Prevention Enoki Mushrooms
(Flammulina velutipes)
‧MycoMagic Hep B prevention enoki mushrooms
Patented strain: MM-Fv-B-001
Deposit No. DSM27789
‧ US patent Application No. 14/464,779
‧ Completed mushroom life cycle and developed fruiting bodies
‧ Stimulated Hep B antibody production in pigs
Desensitization Enoki Mushrooms
(Flammulina velutipes)
Enoki mushrooms transplanted with House Dust Mite Allergen protein Der p2.
Oral vaccinations with mushroom liquid extracts reduce allergic reactions in animals.
MycoMagic Mushroom Molecular Pharming Milestones:
2002：
gpd transformation in Flammulina velutipes
2003：
Establishment of a basidiospore based electroporation methods for F. velutipes and Lentinula edodes
2004：
Establishment of a mycelium based electroporation method
2005：
Successfully expressed GFP in F. velutipes and completed its life cycle
Fluorescent F. velutipes life cycle link
2007：
Establishment of agrobacterium-mediated transformation of F. velutipes.
Coning of carboxin resistance gene in F. velutipes
Development of Hepatitis B prevention L. edodes
Development of desensitization F. velutipes
2009：
Establishment of agrobacterium-mediated transformation of Pleurotus cystidiosus.
2010：
Optimization of gpd promoter in F. velutipes
Acquired patent for gpd promoter cloning in P. cystidiosus,, US patent US7777021
Acquired patent for carboxin resistance gene cloning in F. velutipes, US patent US7759100
2011：
Development of Hepatitis B virus oral vaccine in F. velutipes
Acquired patent for mycelium and basidiospore based electroporation, US patent US7973215
2012：
Development of a homologous selectable system for Hepatitis B prevention
F. velutipes
2013：
Establishment of a platform for multiple gene expressions for F. velutipes
Acquired patent for carboxin resistance gene in F. velutipes, China patent ZL 201010146873.5
Acquired patent for gpd promoter and heterologous gene expression,Taiwan patent I390036
2014：
Patent applications for optimized gpd promoter in F. velutipes,US patent publication US-2014-0123345-A1
Cheers!!! MycoMagic partners with Ganoherb Technology of Fujian, China to tap the vast mainland Chinese market.
...more
